Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 13562
Country/Region: Zambia
Year: 2015
Main Partner: Chreso Ministries
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: HHS/CDC
Total Funding: $3,636,664 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $895,000
Care: TB/HIV (HVTB) $300,000
Care: Pediatric Care and Support (PDCS) $150,000
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $93,077
Testing: HIV Testing and Counseling (HVCT) $101,862
Sexual Prevention: Other Sexual Prevention (HVOP) $261,725
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $100,000
Treatment: Adult Treatment (HTXS) $1,400,000
Treatment: Pediatric Treatment (PDTX) $335,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Age/sex: <1 Female 2016 95
CARE_CURR Age/sex: <1 Male 2016 166
CARE_CURR Age/sex: 1-4 Female 2016 158
CARE_CURR Age/sex: 1-4 Male 2016 124
CARE_CURR Age/sex: 10-14 Female 2016 401
CARE_CURR Age/sex: 10-14 Male 2016 214
CARE_CURR Age/sex: 15-19 Female 2016 1,105
CARE_CURR Age/sex: 15-19 Male 2016 907
CARE_CURR Age/sex: 20-24 Female 2016 2,441
CARE_CURR Age/sex: 20-24 Male 2016 1,950
CARE_CURR Age/sex: 25-49 Female 2016 6,118
CARE_CURR Age/sex: 25-49 Male 2016 4,200
CARE_CURR Age/sex: 5-9 Female 2016 251
CARE_CURR Age/sex: 5-9 Male 2016 165
CARE_CURR Age/sex: 50+ Female 2016 1,878
CARE_CURR Age/sex: 50+ Male 2016 1,337
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 162
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 224
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 2,636
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 1,840
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 21,510
CARE_CURR Sum of Age/Sex disaggregates 2016 21,510
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 4,862
CARE_NEW Age/sex: <1 Female 2016 4
CARE_NEW Age/sex: <1 Male 2016 12
CARE_NEW Age/sex: 1-4 Female 2016 26
CARE_NEW Age/sex: 1-4 Male 2016 40
CARE_NEW Age/sex: 10-14 Female 2016 53
CARE_NEW Age/sex: 10-14 Male 2016 36
CARE_NEW Age/sex: 15-19 Female 2016 133
CARE_NEW Age/sex: 15-19 Male 2016 70
CARE_NEW Age/sex: 20-24 Female 2016 219
CARE_NEW Age/sex: 20-24 Male 2016 190
CARE_NEW Age/sex: 25-49 Female 2016 981
CARE_NEW Age/sex: 25-49 Male 2016 958
CARE_NEW Age/sex: 5-9 Female 2016 22
CARE_NEW Age/sex: 5-9 Male 2016 14
CARE_NEW Age/sex: 50+ Female 2016 102
CARE_NEW Age/sex: 50+ Male 2016 101
CARE_NEW Aggregated Age/sex: <15 Female 2016 105
CARE_NEW Aggregated Age/sex: <15 Male 2016 102
CARE_NEW Aggregated Age/sex: 15+ Female 2016 1,435
CARE_NEW Aggregated Age/sex: 15+ Male 2016 1,319
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 2,961
CARE_NEW Sum of Age/sex disaggregates 2016 2,961
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 2,961
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 2,961
FPINT_SITE Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2016 5
FPINT_SITE Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2016 5
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 194
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 307
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 1,939
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 1,837
HTS_TST By Test Result: Negative 2016 3,634
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 4,251
HTS_TST Sum of Aggregated Age/Sex <15 2016 501
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 3,776
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 4,277
HTS_TST Sum of Test Result disaggregates 2016 4,266
HTS_TST_POS By Test Result: Positive 2016 632
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2016 29
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2016 29
LAB_CAP By clinical laboratories 2016 9
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 9
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 115
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 54
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 61
PMTCT_ARV Sum of New and Current disaggregates 2016 115
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 59
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 64
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 123
PMTCT_EID Sum of Infant Age disaggregates 2016 123
PMTCT_STAT By: Known positives at entry 2016 196
PMTCT_STAT By: Number of new positives identified 2016 711
PMTCT_STAT Number of new ANC and L&D clients 2016 3,215
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 907
PMTCT_STAT Sum of Positives Status disaggregates 2016 907
PP_PREV Age/sex: 10-14 Female 2016 1,113
PP_PREV Age/sex: 10-14 Male 2016 1,016
PP_PREV Age/sex: 15-19 Female 2016 903
PP_PREV Age/sex: 15-19 Male 2016 842
PP_PREV Age/sex: 20-24 Female 2016 859
PP_PREV Age/sex: 20-24 Male 2016 727
PP_PREV Age/sex: 25-49 Female 2016 2,428
PP_PREV Age/sex: 25-49 Male 2016 1,918
PP_PREV Age/sex: 50+ Female 2016 630
PP_PREV Age/sex: 50+ Male 2016 488
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 10,924
PP_PREV Sum of Age/Sex disaggregates 2016 10,924
PP_PREV Total number of people in the target population 2016 1,000
TB_ART Aggregated Age: <15 2016 8
TB_ART Aggregated Age: 15+ 2016 75
TB_ART Female 2016 303
TB_ART Known HIV-positive 2016 50
TB_ART Male 2016 225
TB_ART Sum of Aggregated Age disaggregates 2016 83
TB_ART Sum of Sex disaggregates 2016 528
TB_ART Sum of Test Status disaggregates 2016 50
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 59
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 528
TB_SCREEN Age: <1 2016 225
TB_SCREEN Age: 1-4 2016 285
TB_SCREEN Age: 10-14 2016 527
TB_SCREEN Age: 15-19 2016 835
TB_SCREEN Age: 5-9 2016 408
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 457
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 482
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 21,510
TB_SCREEN Sex: Female 2016 8,311
TB_SCREEN Sex: Male 2016 6,207
TB_SCREEN Sum of Age disaggregates 2016 14,518
TB_SCREEN Sum of Aggregated Age disaggregates 2016 939
TB_SCREEN Sum of Sex disaggregates 2016 14,518
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 14,518
TX_CURR Age/Sex: <1 Female 2016 31
TX_CURR Age/Sex: <1 Male 2016 22
TX_CURR Age/Sex: 1-4 Female 2016 151
TX_CURR Age/Sex: 1-4 Male 2016 163
TX_CURR Age/Sex: 5-14 Female 2016 322
TX_CURR Age/Sex: 5-14 Male 2016 256
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 11,549
TX_CURR Sum of age/sex disaggregates 2016 11,549
TX_NEW Aggregated Grouping by Age: <1 Male 2016 2
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 569
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 426
TX_NEW By Age/Sex: <1 Female 2016 32
TX_NEW By Age/Sex: <1 Male 2016 6
TX_NEW By Age/Sex: 1-4 Female 2016 22
TX_NEW By Age/Sex: 1-4 Male 2016 28
TX_NEW By Age/Sex: 10-14 Female 2016 59
TX_NEW By Age/Sex: 10-14 Male 2016 37
TX_NEW By Age/Sex: 15-19 Female 2016 68
TX_NEW By Age/Sex: 15-19 Male 2016 68
TX_NEW By Age/Sex: 20-24 Female 2016 202
TX_NEW By Age/Sex: 20-24 Male 2016 113
TX_NEW By Age/Sex: 25-49 Female 2016 862
TX_NEW By Age/Sex: 25-49 Male 2016 664
TX_NEW By Age/Sex: 5-9 Female 2016 44
TX_NEW By Age/Sex: 5-9 Male 2016 24
TX_NEW By Age/Sex: 50+ Female 2016 143
TX_NEW By Age/Sex: 50+ Male 2016 72
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 2,454
TX_NEW Sum of Age/Sex disaggregates 2016 2,444
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 995
TX_RET Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at months after initiating ART) 2016 1,017
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 1,910